Zydus Lifesciences, a renowned global pharmaceutical company, has achieved a significant milestone by completing the enrollment for the Phase II clinical trial of its novel oral NLRP3 inflammasome inhibitor, Usnoflast (ZYIL1), aimed at treating patients with Amyotrophic Lateral Sclerosis (ALS). This development marks a pivotal step in addressing the urgent need for effective treatments in […]
Gland Pharma Limited, a prominent player in the generic injectable-focused pharmaceutical industry, has received approval from the United States Food and Drug Administration (USFDA) for its Edaravone Injection. This approval marks a significant milestone for the company as it prepares to offer new therapeutic options for patients suffering from amyotrophic lateral sclerosis (ALS). Product Details […]
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line results of the PHOENIX study, a critical Phase 3 clinical trial investigating the efficacy of AMX0035 (sodium phenylbutyrate and taurursodiol) in treating amyotrophic lateral sclerosis (ALS). Despite the anticipation, the study did not meet its primary endpoint […]